missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Description
- Novel, alkali-tolerant rProtein A ligand withstands rigorous CIP and sanitization procedures with 0.1 to 0.5 M NaOH
- High dynamic binding capacity (DBC) for high titer cultures reduces process time and amount of medium used
- Generic elution profile for different monoclonal antibodies enables platform approach to purification
- High-flow agarose matrix allows the processing of large feed volumes
- Reduces the risk of product contamination and carryover
- Improves performance and reduces overall costs
Spécification
Spécification
| Product Type | Antibody Purification Column |
| Stationary Phase | MabSelect SuRe LX |
| Flow Rate | 4 mL/min. (Max) |
| Ligand | Protein A |
| Particle Size | 85 μm |
| Purification Target | Human IgG |
| Volume (Metric) Bed | 1 mL |
| For Use With (Application) | Purification of Human IgG |
| Sample Volume | 1 to 30 mg/Column |
| Quantity | 5/Pk. |
Sécurité et traitement
Identifiant produit
- HiTrap MabSelect SuRe LX
- Warning
- Flammable liquid Category 3
- H226-Flammable liquid and vapour.
- P241-Use explosion-proof electrical/ventilating/lighting/ equipment.
- P280-Wear protective gloves/protective clothing/eye protection/face protection.
- P305+P351+P338-IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
- P501b-Dispose of contents/container in accordance with local/regional/national/international regulations.
- MIXTURE LIST-Contain: ethanol
- UNKNOWN ACUTE-16.5 per cent of the mixture consists of component(s) of unknown acute toxicity.
Nom du produit
En cliquant sur Soumettre, vous reconnaissez que vous pouvez être contacté par Fisher Scientific au sujet des informations que vous avez fournies dans ce formulaire. Nous ne partagerons pas vos informations à d'autres fins. Toutes les informations de contact fournies seront également conservées conformément à notre politique de confidentialité. Politique de confidentialité.
Vous avez repéré une opportunité d'amélioration ?